In this issue:
Association of SGLT-2 inhibitors with fracture risk in older type 2 diabetes
Access to newer type 2 diabetes medications low–middle-income countries
Tirzepatide vs. glargine in type 2 diabetes: CV risk
Effects of tirzepatide on lipid and metabolite profiles
Severe hypoglycaemia increases incident heart failure risk
Diabetes, hypertension, BMI, smoking and COVID-19-related mortality
Long-term disruption of glycometabolic control after COVID-19
Advanced closed-loop control system improves postprandial glycaemic control
US prevalence trends of diabetes subgroups
Physical fitness and CV risk factors in diabetes subgroups
Please login below to download this issue (PDF)